Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

被引：39
作者：
Lee, Sung Won [1 ,2 ]
Choi, Jonggi [3 ]
Kim, Seung Up [4 ,5 ]
Lim, Young-Suk [3 ]
机构：
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Catholic Univ, Liver Res Ctr, Seoul, South Korea
[3] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
[4] Yonsei Univ, Inst Gastroenterol, Dept Internal Med, Coll Med, Seoul, South Korea
[5] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2021年 / 27卷 / 03期
关键词：
Entecavir; Tenofovir; Hepatitis B; Carcinoma; Hepatocellular; Efficacy; Outcome; DISOPROXIL FUMARATE; RISK; CIRRHOSIS;
D O I：
10.3350/cmh.2021.0179
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
引用
收藏
页码：402 / 412
页数：11
相关论文
共 44 条
[1]   Antitumor activity of Type I and Type III interferons in BNL hepatoma model [J].
Abushahba, Walid ;
Balan, Murugabaskar ;
Castaneda, Ismael ;
Yuan, Yao ;
Reuhl, Kenneth ;
Raveche, Elizabeth ;
de la Torre, Andrew ;
Lasfar, Ahmed ;
Kotenko, Sergei V. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (07) :1059-1071
[2]  
Chang TS, SCI REP-UK, V11, P1365
[3]  
Chen CH, 2020, AM J CANCER RES, V10, P3882
[4]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[5]   Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naive Chronic Hepatitis B Patients in Korea [J].
Choi, HeeKyoung ;
Seo, Gi Hyeon .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (14) :1-10
[6]   Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection [J].
Choi, Jonggi ;
Jo, Chanyoung ;
Lim, Young-Suk .
HEPATOLOGY, 2021, 73 (02) :661-673
[7]   RETRACTED: Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study (Retracted Article) [J].
Choi, Jonggi ;
Kim, Hyo Jeong ;
Lee, Jayoun ;
Cho, Songhee ;
Ko, Min Jung ;
Lim, Young-Suk .
JAMA ONCOLOGY, 2019, 5 (01) :30-36
[8]   Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis [J].
Choi, Won-Mook ;
Choi, Jonggi ;
Lim, Young-Suk .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (02) :246-+
[9]   Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis [J].
Dave, Shravan ;
Park, Sooyoung ;
Murad, M. Hassan ;
Barnard, Abbey ;
Prokop, Larry ;
Adams, Leon A. ;
Singh, Siddharth ;
Loomba, Rohit .
HEPATOLOGY, 2021, 73 (01) :68-78
[10]   EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].
Lampertico P. ;
Agarwal K. ;
Berg T. ;
Buti M. ;
Janssen H.L.A. ;
Papatheodoridis G. ;
Zoulim F. ;
Tacke F. .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398
12345